Co.
Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer
Merck & Co.; Keytruda; pembrolizumab; ovarian cancer; platinum-resistant; overall survival; checkpoint inhibitor; KEYNOTE-B96 trial; progression-free survival; PD-L1
Daiichi and Merck’s Lung Cancer ADC Achieves 48% Response Rate in Pivotal Trial
Daiichi Sankyo; Merck & Co.; ifinatamab deruxtecan; I-DXd; B7-H3; antibody-drug conjugate; ADC; small cell lung cancer; SCLC; IDeate-Lung01; objective response rate; accelerated approval; progression-free survival; overall survival; FDA Breakthrough Therapy Designation
FDA to Decide on Merck’s Subcutaneous Keytruda in September 2025
Subcutaneous Keytruda, FDA decision, September 23, 2025, Merck & Co., cancer treatment, PDUFA date
Merck’s Winrevair Demonstrates Significant Mortality Benefit in Pulmonary Arterial Hypertension Patients
Winrevair, Pulmonary Arterial Hypertension (PAH), Mortality Benefit, Sotatercept, Merck & Co.
Gilead and Merck’s Investigational HIV Combo Shows Promising Long-Term Viral Suppression in Phase 2 Trial
HIV treatment, Weekly oral regimen, Islatravir, Lenacapavir, Viral suppression, Phase 2 clinical trial, Gilead Sciences, Merck & Co.
Merck’s RSV Antibody Clesrovimab Shows Promising Efficacy in Late-Stage Trial
Merck & Co., RSV antibody, Clesrovimab, Respiratory syncytial virus, Infant protection, Late-stage trial results
Merck’s Clesrovimab Shows Promising Results in Preventing RSV Disease and Hospitalizations in Infants
Clesrovimab, Respiratory Syncytial Virus (RSV), RSV Disease Prevention, Infant Health, Monoclonal Antibody, Clinical Trials, Merck & Co.
Merck & Co. Partners with Mestag Therapeutics to Identify Novel Targets for Inflammatory Diseases
Mestag Therapeutics, Merck & Co., Inflammatory diseases, Fibroblast-immune interactions, RAFT platform, Therapeutic targets, Collaboration agreement
Merck & Co. and Mestag Therapeutics Collaborate on $1.9 Billion Fibroblast Therapy Deal for Inflammatory Diseases
Merck & Co., Mestag Therapeutics, Fibroblast therapies, Inflammatory diseases, $1.9 billion deal, RAFT platform, Drug target identification
Merck’s Keytruda and LAG-3 Antibody Combo Fails in Phase 3 Colorectal Cancer Trial
Keytruda, LAG-3, colorectal cancer, Phase 3 trial, Merck & Co., favezelimab, pembrolizumab, KEYFORM-007